Catherine Hall Van Poznak MD

Associate Professor, Medical Oncology
Medical Oncology
Clinical Interests:

Breast Cancer, Osteoporosis and Breast Cancer, Breast Cancer Biomarkers, Bone Metastases

Video profile


U of M Internal Medicine Oncology

Cancer Center Floor 1
1500 E Medical Center Dr SPC 5916
Ann Arbor


Medical School or Training

  • Cornell University Medical College, 1995


  • New York Presbyterian Medical Center (Weill Cornell Med Center), Medicine, NY, 1998


  • Hematology/Medical Oncology, Memorial Sloan Kettering Cancer Center, 2001

Board Certification

  • Medical Oncology


My research concentration is on breast cancer and its relationship with bone. There are three major issues that I research: (1) Osteoporosis as it effects women with breast cancer. Due to the prevalence of low bone mass in the general US population, and the frequency at which women are diagnosed with breast cancer, these two diseases commonly overlap. I am exploring the diagnosis, treatment and the prevention, of osteoporosis in patients with breast cancer (2) Breast cancer biomarkers predictive of site specific relapse (3) Bone metastases. I have several ongoing clinical trials and collaborative laboratory research efforts underway. It is my vision that research will change how we detect, prevent, and treat bone related problems of breast cancer patients.


Dr. Van Poznak received her medical degree from Cornell University Medical College and internal medicine residency training at The New York Hospital-Cornell Medical Center in New York City. Remaining in New York, she completed her fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) and started her oncology practice at MSKCC on the Breast Cancer Medicine Service. In 2006, Dr. Van Poznak joined the faculty of the University of Michigan where she is an active clinician in the Comprehensive Cancer Center's Breast Care Center. Her clinical and translational research is in breast cancer and its relationship to bone - including the diagnosis, treatment and prevention of osteoporosis in breast cancer patients, breast cancer biomarkers predicting site specific relapse, and bone metastases.